{{Rsnum
|rsid=11222869
|Gene=NTM
|Chromosome=11
|position=132031854
|Orientation=plus
|GMAF=0.4982
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=NTM
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 26.5 | 57.5 | 15.9
| HCB | 3.6 | 33.6 | 62.8
| JPT | 0.9 | 29.2 | 69.9
| YRI | 66.7 | 27.2 | 6.1
| ASW | 40.4 | 49.1 | 10.5
| CHB | 3.6 | 33.6 | 62.8
| CHD | 3.7 | 36.7 | 59.6
| GIH | 25.7 | 42.6 | 31.7
| LWK | 52.7 | 39.1 | 8.2
| MEX | 37.9 | 48.3 | 13.8
| MKK | 38.5 | 45.5 | 16.0
| TSI | 29.4 | 52.0 | 18.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11222869
|Name_s=
|Gene_s=NTM
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs10018204, rs11222869, rs16965867, rs1846644, and rs6539870 were significant predictors of etoposide IC50, accounting for 55% of the etoposide IC50 variation in Caucasians. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00009. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109415
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11222869
|overall_frequency_n=60
|overall_frequency_d=128
|overall_frequency=0.46875
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=46
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | NatGeo2}}